NFKB1 and Miyoshi myopathy: Beyond MM, bortezomib has demonstrated the ability to alleviate skin lesions in an imiquimod-induced psoriatic mouse model, in which it inhibits NLRP3 inflammasome activation and NF-κB signaling, reducing psoriatic inflammation [462].